Validated targets to high-potential lead series
At Ausovi, Structure-Based Lead Generation represents the pivotal moment where scientific rigor converges with chemical creativity to transform a rigorously validated target into a portfolio of high-quality, chemically tractable, and IP-protectable lead series. Once a target has been thoroughly identified and biologically confirmed through our disciplined upstream process, we transition directly into this decisive phase, which serves as the critical bridge to analog optimization and preclinical advancement.
We employ a fully integrated, in-house structure-based approach that begins with high-resolution structural biology—utilizing techniques such as X-ray crystallography and cryo-EM—to capture atomic-level insights into target-ligand interactions. These structural foundations enable fragment-based screening and rational scaffold design to uncover novel, drug-like starting points with genuine chemical novelty. From there, we execute iterative, structure-guided design cycles powered by molecular dynamics simulations, free-energy perturbation calculations, and quantum mechanical methods to systematically enhance binding affinity, selectivity, and overall physicochemical properties.
Parallel synthesis of focused analog libraries follows, with real-time structure-activity relationship (SAR) data feeding directly back into the design loop. Concurrently, we conduct early multiparameter optimization to balance potency and selectivity while addressing key drug-like attributes—solubility, permeability, metabolic stability, and minimization of off-target liabilities. Throughout this resource-intensive phase, our IP strategy remains tightly integrated, with strategic provisional patent filings secured around novel chemical matter and unique binding modes while the lead-generation window remains open.
By maintaining complete internal control over structure-based lead generation, Ausovi guarantees that every lead series emerges mechanistically differentiated and superior to existing literature compounds. Each series is built on robust, high-quality starting points that offer clear pathways to strong composition-of-matter protection, is optimized early for favorable drug-like properties to minimize downstream attrition, and is deliberately positioned for seamless and accelerated progression into hit-to-lead and full lead optimization.
This phase is intentionally resource-intensive because it defines the chemical foundation of the entire program. A well-executed structure-based lead series dramatically elevates the probability of success across preclinical toxicology, formulation development, and eventual clinical translation—ensuring that only the most promising, differentiated, and protectable candidates advance into the next stages of Ausovi’s pipeline.
Structure-Based Lead Generation Challenge
The Structure-Based Lead Generation Challenge Many discovery programs stall or fail because they advance weak or unprotectable chemical starting points: high micromolar hits, frequent off-target activity, poor synthetic tractability, or narrow IP windows that limit freedom to operate.
Ausovi addresses this head-on by making Structure-Based Lead Generation the central engine of our pipeline. Through atomic-level structural insights, fragment-to-lead expansion, and multiparameter optimization, we generate differentiated lead series that are: Designed for favorable pharmacokinetics and safety margins early on.
labstica list
- Atomic-resolution structural data driving rational design
- Fragment-based and scaffold-hopping strategies for novelty
- Real-time SAR feedback loops with parallel synthesis
- Early profiling across potency, selectivity, ADME, and safety
- Provisional patent filings during lead-generation window
- Clear lead series criteria before committing to lead optimization
- Higher probability of first-in-class or best-in-class potential